CA2719766C - Method and compositions for treatment of cancer - Google Patents

Method and compositions for treatment of cancer Download PDF

Info

Publication number
CA2719766C
CA2719766C CA2719766A CA2719766A CA2719766C CA 2719766 C CA2719766 C CA 2719766C CA 2719766 A CA2719766 A CA 2719766A CA 2719766 A CA2719766 A CA 2719766A CA 2719766 C CA2719766 C CA 2719766C
Authority
CA
Canada
Prior art keywords
cancer
treatment
cisplatin
cancer agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2719766A
Other languages
English (en)
French (fr)
Other versions
CA2719766A1 (en
Inventor
Angelika Burger
Hans Hendriks
Bernardus Rademaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOMINOX Inc
Original Assignee
KOMINOX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOMINOX Inc filed Critical KOMINOX Inc
Publication of CA2719766A1 publication Critical patent/CA2719766A1/en
Application granted granted Critical
Publication of CA2719766C publication Critical patent/CA2719766C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2719766A 2008-03-27 2009-03-24 Method and compositions for treatment of cancer Active CA2719766C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3998708P 2008-03-27 2008-03-27
US61/039,987 2008-03-27
US12/408,864 2009-03-23
US12/408,864 US20090246291A1 (en) 2008-03-27 2009-03-23 Method and compositions for treatment of cancer
PCT/US2009/038104 WO2009120697A2 (en) 2008-03-27 2009-03-24 Method and compositions for treatment of cancer

Publications (2)

Publication Number Publication Date
CA2719766A1 CA2719766A1 (en) 2009-10-01
CA2719766C true CA2719766C (en) 2017-10-31

Family

ID=41114644

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2719766A Active CA2719766C (en) 2008-03-27 2009-03-24 Method and compositions for treatment of cancer

Country Status (20)

Country Link
US (2) US20090246291A1 (enExample)
EP (1) EP2268292B1 (enExample)
JP (2) JP5543956B2 (enExample)
KR (1) KR101634138B1 (enExample)
CN (2) CN102046187A (enExample)
AU (1) AU2009228378B2 (enExample)
BR (1) BRPI0909164A2 (enExample)
CA (1) CA2719766C (enExample)
CY (1) CY1120536T1 (enExample)
DK (1) DK2268292T3 (enExample)
ES (1) ES2656762T3 (enExample)
HU (1) HUE036609T2 (enExample)
LT (1) LT2268292T (enExample)
MX (1) MX2010010621A (enExample)
PL (1) PL2268292T3 (enExample)
PT (1) PT2268292T (enExample)
RU (1) RU2508116C2 (enExample)
SI (1) SI2268292T1 (enExample)
WO (1) WO2009120697A2 (enExample)
ZA (1) ZA201006988B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
PL2475362T3 (pl) * 2009-09-10 2019-09-30 Kominox, Inc. Terapia celowana w nowotworowe komórki macierzyste i raka lekoopornego
US8795738B2 (en) * 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
WO2012012305A2 (en) * 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
MX336761B (es) * 2010-08-24 2016-01-29 Univ Tennessee Res Foundation Compuestos para el tratamiento de cancer.
WO2012131487A2 (en) * 2011-03-30 2012-10-04 Kominox, Inc. Compositions and methods for the treatment of cancer
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
WO2012155061A1 (en) * 2011-05-12 2012-11-15 Board Of Regents, University Of Texas System Use of arsenic for cancer therapy protection
KR101309844B1 (ko) 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
AU2014290012B2 (en) * 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
AU2017368444B9 (en) 2016-12-01 2020-07-02 Eupharma Pty Ltd Arsenic compositions
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
CN116236505A (zh) * 2023-03-15 2023-06-09 上海市第四人民医院 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
ES2944907T3 (es) * 2002-04-10 2023-06-27 Komipharm Int Co Ltd Uso de meta-arsenito de sodio para el tratamiento de tumores
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies

Also Published As

Publication number Publication date
EP2268292A4 (en) 2011-05-11
LT2268292T (lt) 2018-03-26
PL2268292T3 (pl) 2018-06-29
RU2010143893A (ru) 2012-05-10
WO2009120697A2 (en) 2009-10-01
AU2009228378B2 (en) 2014-07-17
DK2268292T3 (en) 2018-03-12
EP2268292A2 (en) 2011-01-05
JP2014101387A (ja) 2014-06-05
BRPI0909164A2 (pt) 2016-06-21
ES2656762T3 (es) 2018-02-28
MX2010010621A (es) 2011-04-05
JP2011515481A (ja) 2011-05-19
EP2268292B1 (en) 2017-12-27
HUE036609T2 (hu) 2018-07-30
SI2268292T1 (en) 2018-03-30
CA2719766A1 (en) 2009-10-01
AU2009228378A1 (en) 2009-10-01
CN102046187A (zh) 2011-05-04
ZA201006988B (en) 2012-05-30
WO2009120697A4 (en) 2010-04-15
PT2268292T (pt) 2018-02-19
CY1120536T1 (el) 2019-07-10
JP5543956B2 (ja) 2014-07-09
WO2009120697A3 (en) 2010-02-18
US20180055812A1 (en) 2018-03-01
KR20110009664A (ko) 2011-01-28
US20090246291A1 (en) 2009-10-01
KR101634138B1 (ko) 2016-06-28
CN104997808A (zh) 2015-10-28
RU2508116C2 (ru) 2014-02-27

Similar Documents

Publication Publication Date Title
AU2009228378B2 (en) Method and compositions for treatment of cancer
US12336992B2 (en) PAC-1 combination therapy
EP2049121B1 (en) Compositions for promoting activity of anti-cancer therapies
KR102569221B1 (ko) 공결정 조성물 및 그의 약제학적 용도
AU2017254774B2 (en) Chemotherapy improvements
EP1206256B1 (en) Combination therapy using pentafluorobenzenesulfonamide and platin compound
AU2012209100A1 (en) Combinations
EP1729808B1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11
CN111514140B (zh) 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
EP3565547B1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
AU2004255023B2 (en) Combination therapy
HK1152250A (en) Method and compositions for treatment of cancer
HK1152250B (en) Method and compositions for treatment of cancer
Göksel et al. Single-agent oral etoposide in patients with relapsed or refractory extensive small-cell lung cancer
KR20060036058A (ko) 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물
EP4561577A1 (en) Cancer combination therapy including a flt3-inhibitor
HK1253828B (en) Pac-1 combination therapy
HK1096023B (en) Combination therapy with azd2171 and 5-fu and/or cpt-11

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251023

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260505